Navigation Links
Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
Date:11/27/2007

System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with Excaliard Pharmaceuticals and the discovery and development of Isis' antisense drugs for the local treatment of fibrotic diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended September 30, 2007, which are on file with the SEC. Copies of th
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Recovery Resources Collaborates with Two Nonprofit Agencies for Children of Alcoholics Outreach Program
2. MU researchers to collaborate on $20 million project
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
5. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
6. Rosecrance and Chicagos Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
7. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
8. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
9. SAIC to Collaborate with UK Biometrics Institute
10. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
11. ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 The Workgroup for ... authority on the use of health IT to ... full agenda for its annual fall conference, WEDI-Con ... WEDI-Con 2014 will take place at the HYATT ... attracting a diverse cross-section of payers, providers, government ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 Online Health ... 2015. , According to Zane Benefits, with open enrollment ... are encouraged to start thinking about their healthcare needs. ... enrollment period will run from November 15, 2014 to ... purchase a new individual health insurance policy, or switch ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Attendees ... get a sneak peak at Los Angeles’ first multi-faceted ... a tour of a blossoming 1.5-acre high school campus ... a shipping container farm in the L.A. Art District. ... diversity of sustainable urban agriculture, will kick off Seedstock’s ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3
... and treated in many cases, say US doctors. In peripheral ... become blocked with the same kind of fatty deposits - ... of treating it is very simple - keep walking. While ... the ability to walk with ease. Positive effects are seen ...
... Nearly half of people with Parkinson's disease are using one ... as vitamins, message or acupuncture. Researchers at Johns Hopkins University ... than 200 people with Parkinson's disease. Forty per cent use ... cent use five or more different ones. There's no link ...
... Bubonic plague, the bacterium blamed for the Black Death ... biological weapon, has had its entire genome sequenced. The ... and picking up new genes from other microbes. ,That ... emerge. More ominously, it suggests that enhanced strains might ...
... with a skin condition called contact dermatitis may benefit from ... tomatoes, according to the results of a small study.// Individuals ... they come in contact with substances they are allergic to. ... the skin, and many people may not realize foods can ...
... New research confirms that the main ingredient in the -- ... loss when used long term. The younger you are when ... bone-related problems later in life. // ... our bone mass is constantly breaking down and re-building, usually ...
... Suppression of testosterone levels in men with testicular ... disease, warn US researchers.,A research team from North ... levels go down, a high rise in levels ... disease – occurs. They suggest that this phenomenon ...
Cached Medicine News:Health News:Sequencing of the Plague 2
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the ... that its " Easy Blog " - has received more than ...   "We are thrilled that so many people are ... , CEO of Easy Breathe. "We,re committed to making sleep apnea ... Blog to stay informed about sleep apnea news , ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19
... , , , OSAKA, Japan, ... announced today positive results from PEARL 2 - a ... In this trial, both lurasidone 40 and 120 mg/day were significantly more ... an overall discontinuation rate that was similar to placebo. , , ...
... , , , ... CXM ) today announced that all patients enrolled in the Company,s ... and that it plans to provide detailed safety and efficacy data ... http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase 2b MATRIX ...
Cached Medicine Technology:Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 2Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 3Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 4Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
... Greenspec Laryngoscopes are a high quality fiberoptic ... bringing greater standardization to fiberoptic laryngoscopes. The ... and indicates it's ability to interconnect with ... light offers a cool, bright and focused ...
... steel. Lamp supplied with blade. Oxygen ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
Medicine Products: